Coexpression cluster:C398
From FANTOM5_SSTAR
Full id: C398_neuroepithelioma_neuroectodermal_carcinoid_neuroblastoma_spinal_brain_synovial
Phase1 CAGE Peaks
Enriched pathways on this co-expression cluster<b>Summary:</b><br>Canonical pathway gene sets were compiled from Reactome, Wikipathways and KEGG. For the major signaling pathways, the transcriptionally-regulated genes (downstream targets) were obtained from Netpath. Combined, the canonical pathways and downstream targets totaled 489 human gene sets. The corresponding M. musculus gene sets were inferred by homology using the HomoloGene database. Enrichment for each of the canonical 489 pathways and gene sets included in the co-expression cluster was assessed by the hypergeometric probability. The resulting P values were also then adjusted by the Benjamini-Hochberg method for multiple comparisons.<br><b>Analyst: </b>Emmanuel Dimont<br><br>link to source dataset<br>data
No results for this coexpression
Enriched Gene Ontology terms on this co-expression cluster<b>Summary:</b> Results for GOStat analysis on co-expressed clusters. Each cluster with promoters mapping to at least two different genes was analysed with GOStat (PMID: 14962934) with default parameter. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br>data
GO ID | GO name | FDR corrected p-value |
---|---|---|
GO:0043565 | sequence-specific DNA binding | 0.00116055591153121 |
GO:0003700 | transcription factor activity | 0.00493005322372769 |
GO:0015052 | beta3-adrenergic receptor activity | 0.00825679971741433 |
GO:0021529 | spinal cord oligodendrocyte cell differentiation | 0.00825679971741433 |
GO:0045944 | positive regulation of transcription from RNA polymerase II promoter | 0.00875366199758637 |
GO:0007275 | multicellular organismal development | 0.00875366199758637 |
GO:0051380 | norepinephrine binding | 0.00880530874965199 |
GO:0048522 | positive regulation of cellular process | 0.00880530874965199 |
GO:0045817 | positive regulation of global transcription from RNA polymerase II promoter | 0.00880530874965199 |
GO:0048518 | positive regulation of biological process | 0.00880530874965199 |
GO:0045893 | positive regulation of transcription, DNA-dependent | 0.00880530874965199 |
GO:0050794 | regulation of cellular process | 0.00880530874965199 |
GO:0006358 | regulation of global transcription from RNA polymerase II promoter | 0.00880530874965199 |
GO:0048665 | neuron fate specification | 0.00880530874965199 |
GO:0004939 | beta-adrenergic receptor activity | 0.00880530874965199 |
GO:0050789 | regulation of biological process | 0.00939786051904262 |
GO:0045941 | positive regulation of transcription | 0.00939786051904262 |
GO:0045935 | positive regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process | 0.00939786051904262 |
GO:0021515 | cell differentiation in spinal cord | 0.00939786051904262 |
GO:0031018 | endocrine pancreas development | 0.00939786051904262 |
GO:0032502 | developmental process | 0.00939786051904262 |
GO:0006355 | regulation of transcription, DNA-dependent | 0.00939786051904262 |
GO:0006351 | transcription, DNA-dependent | 0.00939786051904262 |
GO:0032774 | RNA biosynthetic process | 0.00939786051904262 |
GO:0014003 | oligodendrocyte development | 0.00939786051904262 |
GO:0015277 | kainate selective glutamate receptor activity | 0.00939786051904262 |
GO:0043410 | positive regulation of MAPKKK cascade | 0.00939786051904262 |
GO:0003677 | DNA binding | 0.00939786051904262 |
GO:0065007 | biological regulation | 0.00939786051904262 |
GO:0045449 | regulation of transcription | 0.00939786051904262 |
GO:0031325 | positive regulation of cellular metabolic process | 0.00939786051904262 |
GO:0046983 | protein dimerization activity | 0.00939786051904262 |
GO:0031016 | pancreas development | 0.00939786051904262 |
GO:0021510 | spinal cord development | 0.00939786051904262 |
GO:0019219 | regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process | 0.00939786051904262 |
GO:0009893 | positive regulation of metabolic process | 0.00939786051904262 |
GO:0048709 | oligodendrocyte differentiation | 0.00939786051904262 |
GO:0006350 | transcription | 0.00939786051904262 |
GO:0032501 | multicellular organismal process | 0.00939786051904262 |
GO:0010468 | regulation of gene expression | 0.00939786051904262 |
GO:0031323 | regulation of cellular metabolic process | 0.00997615312025724 |
GO:0006357 | regulation of transcription from RNA polymerase II promoter | 0.00997615312025724 |
GO:0021782 | glial cell development | 0.00997615312025724 |
GO:0048663 | neuron fate commitment | 0.0104193052793127 |
GO:0043408 | regulation of MAPKKK cascade | 0.0104193052793127 |
GO:0001708 | cell fate specification | 0.0104193052793127 |
GO:0004935 | adrenoceptor activity | 0.0104193052793127 |
GO:0019222 | regulation of metabolic process | 0.0104193052793127 |
GO:0016070 | RNA metabolic process | 0.0104193052793127 |
GO:0048856 | anatomical structure development | 0.0134138326126212 |
GO:0007215 | glutamate signaling pathway | 0.0135794335084424 |
GO:0007190 | adenylate cyclase activation | 0.0145845525423315 |
GO:0045762 | positive regulation of adenylate cyclase activity | 0.0153058715131997 |
GO:0031281 | positive regulation of cyclase activity | 0.0153058715131997 |
GO:0051349 | positive regulation of lyase activity | 0.0153058715131997 |
GO:0042562 | hormone binding | 0.0153058715131997 |
GO:0006366 | transcription from RNA polymerase II promoter | 0.0164796078645652 |
GO:0010001 | glial cell differentiation | 0.0164796078645652 |
GO:0035270 | endocrine system development | 0.0184293903317657 |
GO:0007399 | nervous system development | 0.0190433330980239 |
GO:0001822 | kidney development | 0.0190433330980239 |
GO:0042063 | gliogenesis | 0.0190433330980239 |
GO:0004970 | ionotropic glutamate receptor activity | 0.0190433330980239 |
GO:0007189 | G-protein signaling, adenylate cyclase activating pathway | 0.0190433330980239 |
GO:0005234 | extracellular-glutamate-gated ion channel activity | 0.0197609833425238 |
GO:0001655 | urogenital system development | 0.0199591205669183 |
GO:0045761 | regulation of adenylate cyclase activity | 0.0200429495925894 |
GO:0031279 | regulation of cyclase activity | 0.0200429495925894 |
GO:0051339 | regulation of lyase activity | 0.0200429495925894 |
GO:0010467 | gene expression | 0.0202245390867495 |
GO:0043176 | amine binding | 0.0204028976861871 |
GO:0045597 | positive regulation of cell differentiation | 0.0214865664443413 |
GO:0006112 | energy reserve metabolic process | 0.0247581429427409 |
GO:0006139 | nucleobase, nucleoside, nucleotide and nucleic acid metabolic process | 0.0247581429427409 |
GO:0005634 | nucleus | 0.0278121819963144 |
GO:0008227 | amine receptor activity | 0.0289750242419746 |
GO:0051094 | positive regulation of developmental process | 0.0290234365138574 |
GO:0045165 | cell fate commitment | 0.0299087690292912 |
GO:0005231 | excitatory extracellular ligand-gated ion channel activity | 0.029943891968136 |
GO:0003676 | nucleic acid binding | 0.0314626919076973 |
GO:0007188 | G-protein signaling, coupled to cAMP nucleotide second messenger | 0.0340418938006602 |
GO:0019933 | cAMP-mediated signaling | 0.0348107586320543 |
GO:0048513 | organ development | 0.0348107586320543 |
GO:0008066 | glutamate receptor activity | 0.0364148977951553 |
GO:0043170 | macromolecule metabolic process | 0.0364148977951553 |
GO:0048468 | cell development | 0.0394914210203462 |
GO:0043235 | receptor complex | 0.0414249758746352 |
GO:0007187 | G-protein signaling, coupled to cyclic nucleotide second messenger | 0.0429729248948776 |
GO:0015980 | energy derivation by oxidation of organic compounds | 0.0429729248948776 |
GO:0005887 | integral to plasma membrane | 0.0429729248948776 |
GO:0031226 | intrinsic to plasma membrane | 0.0434087731362005 |
GO:0019935 | cyclic-nucleotide-mediated signaling | 0.0434087731362005 |
GO:0005230 | extracellular ligand-gated ion channel activity | 0.0460793535836692 |
GO:0007420 | brain development | 0.0483447649736714 |
GO:0045595 | regulation of cell differentiation | 0.0493591462687715 |
GO:0042165 | neurotransmitter binding | 0.0493591462687715 |
Enriched sample ontology terms on this co-expression cluster<b>Summary:</b>To summarize promoter activities (expression profile of a TSS region) across ~1000 samples, we performed enrichment analysis based on FANTOM5 Sample Ontology (FF ontology). The question here is “in which type of samples the promoter is more active”. To answer this question, we compared expressions (TPMs) in the samples associated with a sample ontology term and the rest of the samples by using the Mann-Whitney rank sum test. To summarize ontologies enriched in this co-expression cluster, we ran the same analysis on an averaged expression profile of all promoters that make up. <b>Analyst:</b> Hideya Kawaji <br><br>links to source dataset<br><br><br>uberon_data<br>disease_data<br>
Ontology term | p-value | n |
---|---|---|
sympathetic nervous system | 1.28e-23 | 5 |
autonomic nervous system | 1.28e-23 | 5 |
neural tissue | 1.15e-15 | 2 |
peripheral nervous system | 1.31e-13 | 8 |
Ontology term | p-value | n |
---|---|---|
neuroectodermal tumor | 1.54e-70 | 10 |
germ cell and embryonal cancer | 2.03e-32 | 22 |
germ cell cancer | 2.03e-32 | 22 |
neuroendocrine tumor | 7.13e-20 | 6 |
peripheral nerve sheath neoplasm | 1.15e-15 | 2 |
neurofibroma | 1.15e-15 | 2 |
peripheral nervous system neoplasm | 6.73e-11 | 3 |
Overrepresented TFBS (DNA) motifs on this co-expression cluster<b>Summary:</b>The values shown are the p-values for overrepresentation of the motif in this coexpression cluster. So a small p-value means a strong overrepresentation. <b>Analyst:</b> Michiel de Hoon <br><br>link to source data <br> Novel motifs <br>data <br><br> Jaspar motifs <br>data
Novel motifs
JASPAR motifs
Motifs | -log10(p-value) |
---|---|
{{{tfbs_overrepresentation_jaspar}}} |
ENCODE TF ChIP-seq peak enrichment analysis<b>Summary:</b> For each TF and each co-expression cluster, the number of promoters with ENCODE TF ChIP signal was compared with the rest of promoters from the robust set using Fisher's exact test. Clusters with significant ChIP enrichment (q <= 0.05) after Benjamini-Hochberg correction were retained. <br><b>Analyst:</b> Erik Arner<br><br>link to source dataset<br><br>data
(#promoters = Number of promoters in this coexpression cluster that have ChIP signal of the TF)
TF | #promoters | Enrichment | p-value | q-value |
---|---|---|---|---|
MAFF#23764 | 3 | 6.49792574883983 | 0.0107214750985517 | 0.0395751798196663 |
Relative expression of the co-expression cluster<b>Summary:</b>Co-expression clusters are compared against FANTOM5 samples to obtain relative expression. <br><b>Analyst:</b>NA<br><br>link to data source<br> data
This analysis result is provided for C0 - C305 clusters.